Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00407407
Status:
TERMINATED
Last Update Posted:
2019-10-18
First Post:
2006-12-01
Brief Title:
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian Primary Peritoneal or Fallopian Tube Carcinoma
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian Primary Peritoneal or Fallopian Tube Carcinoma
Status:
TERMINATED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
MTD not determined
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities DLTs of weekly and every 3-weeks ABI-007 in combination with carboplatin area under the curve AUC6 in patients with ovarian cancer primary peritoneal cancer or fallopian tube cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None